What the FDA labels say about taking them together
Finerenone and nirmatrelvir/ritonavir
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names finerenone in its contraindications section; the finerenone label PlainMeds reads does not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “Co-administration contraindicated due to potential for serious adverse reactions including hyperkalemia, hypotension, and hyponatremia.”
Check it at the source: the finerenone FDA label on DailyMed (effective August 28, 2025, Bayer HealthCare Pharmaceuticals Inc.); the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the finerenone label say about nirmatrelvir/ritonavir?
Finerenone's label (effective August 28, 2025) does not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Kerendia), Bayer HealthCare Pharmaceuticals Inc., effective August 28, 2025 (SPL set fc726765-5d5a-4d6e-b037-b847bda9fb7c), via openFDA; the full label on DailyMed
What does the nirmatrelvir/ritonavir label say about finerenone?
Nirmatrelvir/ritonavir label, contraindicationsMineralocorticoid receptor antagonists: finerenone
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: Mineralocorticoid receptor antagonists; Drugs within Class: finerenone; Effect on Concentration: ↑ finerenone; Clinical Comments: Co-administration contraindicated due to potential for serious adverse reactions including hyperkalemia, hypotension, and hyponatremia [see ].
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Finerenone | Nirmatrelvir/ritonavir | |
|---|---|---|
| Labeled for | Chronic kidney disease | COVID-19 |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $22.86 per tablet 10 mg tablet | $49.24 per unit 300-100 mg dose pack |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once